Brief: Pledpharma To Acquire Rare Thyroid Therapeutics

Egetis Therapeutics AB (publ)

05/10/2020 07:09

Oct 5 (Reuters) - PledPharma AB (publ)  PLED.ST :
    * TO ACQUIRE RARE THYROID THERAPEUTICS, CREATING A NEW
FOCUSED
ORPHAN DRUG DEVELOPMENT COMPANY
    * PURCHASE PRICE FOR SHARES IN RTT CONSISTS OF A CASH
PURCHASE
PRICE IN AMOUNT OF 60 MSEK, FUNDED FROM OWN CASH-IN-HAND, WHICH
WILL BE PAID ON CLOSING AND A SHARE PURCHASE PRICE CONSISTING OF
63,773,345 NEW SHARES IN PLEDPHARMA.
    * TRANSACTION IS EXPECTED TO BE COMPLETED IN EARLY NOVEMBER
2020
    * CARRIES OUT A FULLY GUARANTEED RIGHTS ISSUE OF APPROX. 200
MSEK
TO FINANCE DEVELOPMENT OF EMCITATE AND ALADOTE TO MARKET
APPROVAL AND INITIAL COMMERCIAL PREPARATIONS
    * SUBSCRIPTION PRICE IN RIGHTS ISSUE IS SEK 5.25 PER SHARE
    * BOARD INTENDS TO SUMMON EXTRAORDINARY GENERAL MEETING TO
DECIDE
ON CHANGING COMPANY'S NAME FROM PLEDPHARMA AB TO EGETIS
THERAPEUTICS AB

Source text for Eikon:  ID: 
Further company coverage:  PLED.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))